ARTICLE | Deals
The deal grows Novartis’ ligand modality and chelator toolbox, and its focus on Lutathera target SSTR2
By Karen Tkach Tuzman, Director of Biopharma Intelligence
November 20, 2024 12:55 AM UTC
Beyond the big acquisitions that put Novartis on the map as a radiopharmaceutical trailblazer are strings of smaller deals providing specialized subcomponents for the modular modality. Monday’s Ratio Therapeutics partnership adds PK-optimization and radioisotope chelation platforms to the list, and shows the pharma is looking for next-generation follow-ups to its Lutathera franchise.
In a deal announced Nov. 18, Ratio Therapeutics Inc. will deploy its technology platforms to develop an SSTR2-targeting radiopharmaceutical in collaboration with Novartis AG (SIX:NOVN; NYSE:NVS), making it eligible for up to $745 million in upfront and milestone payments, plus tiered royalties. The partners will collaborate on preclinical research and candidate selection, and Novartis will conduct all subsequent development, manufacturing and commercialization activities…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654236/where-the-ratio-deal-fits-into-novartis-radiopharma-matrix